Resistance to activated protein C in thalassaemic patients: An underlying cause of thrombosis

European Journal of Haematology

Volumn 61, Issue 2, 1998, Pages 123-127

  Giordano, P ^a   Del Vecchio, G C ^a   Altomare, M ^a   Coppola, B ^a   Schettini, F ^a   Iolascon, A ^a,b   De Mattia, D ^a  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

Author keywords

APCR; Arterial thrombosis; Factor V Leiden; Thalassaemia; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE MUTATION; GENE STRUCTURE; HEMATOCRIT; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THALASSEMIA; THROMBOGENESIS; THROMBOPHILIA; THROMBOSIS;

EID: 0031826752     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01072.x     Document Type: Article

References (32)

1. MICHAELI J, MITTLEMANN M, GRISARU D, RACHMILEWITZ E. Thromboembolic complications in beta thalassemia major. Acta Haematol 1992: 87: 71-74.
2. LOGOTHETIS J, CONSTANTOULAKIS M, ECONOMIDOU J, et al. Thalassemia major (homozygous beta-thalassemia): a survey of 38 cases with emphasis on neurologic and muscular aspects. Neurology 1972: 22: 294-304.
3. SINNIAH D. VEGNAENDRA V, KAMMARUDDIN A. Neurological complications of beta-thalassemia major. Arch Dis Child 1997: 52: 977-979.
4. DEL PRINCIPE D, MENICHLLLI, A, DI GIULIO S, DE MATTEIS W, CIANCIULLI P, PAPA G. PADGEM/GMP 140 expressions on platelet membranes from homozygous beta-thalassaemic patients. Br J Haematol 1993: 84: 111-117.
5. ELDOR A, LELLOUCHE F, GOLDFARB A, RACHWILEWITZ EA, MACLOUF J. In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood 1991: 77: 1749-1753.
6. SCHETTINI F. DE MATTIA D, ARCAMONE G, et al. Coagulation contact phase factors and inhibitors in Beta-Thalassemia major children. Pediatr Hematol Oncol 1987: 4: 231-236.
7. SHIRAHATA A, FUNAHARA Y, OPARTKIATTIKUL N, FUCHAROEN S, LAOSOMBAT V, YAMADA K. Protein C and S deficiency in thalassemic patients Southeast Asian J Trop Med Public Health 1992: 23 (suppl 2): 65-73.
8. BEN-YASHAR W, BARENHOLTZ Y, HY-AM E, RACHMILEWITZ E, ELDOR A. Phosphatidilserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulablc state and thrombotic episodes. Am J Hematol 1993: 44: 63-65.
9. O' DRISCOLI A, MACKIE IJ, PORTER JB, MACHIN, SJ. Low plasma heparin cofactor II levels in Thalassemia syndromes are corrected by chronic blood transfusion. Br J Haematol 1995: 90: 65-70.
10. SVENNSON P, DAHLBACK B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994: 330: 517-522.
11. BERTINA R, KOELEMAN B, KOSTFR T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994: 369: 64-67.
12. KOSTER T, ROSENDAAL F, DE RONDE H, BRIET E, VANDENBROUCKE J, BERTINA R. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993: 342: 1503-1506.
13. DAHLHACK B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995: 85: 607-614.
14. MARTINELLI I, CATTANEO M, PANZERI D, MANNUCCI PM. Low prevalence of factor V 506Q in patients with isolated pulmonary embolism. Blood 1996: 88 (suppl 1): 172a.
15. JOROUERA JI, MONTORO JM, FERNANDKZ MA, AZNAR JA, AZNAR J. Modiified test for activated protein C resistence. Lancet 1994: 344: 1162-1163.
16. TROSSAERT M, CONARD J. HORELLOU MH, et al. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994: 344: 1709-1712.
17. DE RONDE H, BERTINA RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemostas 1994: 72: 880-886.
18. EXNER T, TRIPLETT DA, TABERNER D, MACHIN SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC subcommittee for the standardization of lupus anticoagulants. Thromb Haemostas 1991: 65: 320-322.
19. SIFONTES MT, NUSS R, JACOBSON LJ, GRIFFIN JH, MANCO-JOHNSON MJ. Thrombosis in otherwise well children with the factor V Leiden mutation. J Pediatr 1996: 128: 324-328.
20. NOWAK-GOTTL U, KOCH HG, ASCHKA I, KOHLHASE B, VIELHABER H, KUSLEMANN G. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol 1996: 92: 992-998.
21. PETAJA J, JALANKO H, HOLMBERG C, KINNUNEN S, SYRJALA M. Resistance to activated protein C as an underlying cause of recurrent venous thrombosis during relapsing nephrotic syndrome. J Pediatr 1995: 127: 103-105.
22. KOHLASE B, VIELHABER H, KEHL HG, KECFCIOGLU D, KOCH HG, NOWAK-GOTTL U. Thromboembolism and resistance to activated protein C in children with underlying cardiac disease. J Pediatr 1996: 129: 677-679.
23. WRIGHT JG, COOPER P, MALIA RG, et al. Activated protein C resistance in homozygous sickle cell disease. Br J Haematol 1997: 96: 854-856.
24. SIFONTES MT, NUSS R, HUNGER SP, WILIAMS J, JACOBSON LJ, MANCO-JOHNSON MJ. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 1997: 96: 484-489.
25. BOWEN DJ, STANDEN GR. Genetic detection of Factor V Leiden: the question of specificity. Br J Haematol 1997: 97: 691-692.
26. ABOUD MR, MA DDF. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation. Br J Haematol 1997: 97: 798-803.
27. BOKAREWA MI, BREMME K, FALK G, STEN-LINDKR M, EGBERG N, BLOMBACK M. Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene. Thromb Res 1995: 78: 193-200.
28. GUMMING AM, TAIT RC, FILDES S, YOONG A, KEENEY S, HAY CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995: 90: 725-727.
29. VANDERBROUCKE JP, KOSTER T, BRIECK E, REITSMA PH, BERTINA RM, ROSENDAAL FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994: 344: 1453-1457.
30. HENKENS CMA, BOM VJJ, VAN DER MEER J. Lowered APC sensitivity ratio related to increased factor VIII clotting activity. Thromb Haemostas 1995: 74: 1198-1199.
31. AL-SAFED A, MAKRIS M, MALIA RG, PRESTON FE. GREAVES M. The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C. Br J Haematol 1994: 88: 845-848.
32. LIEBMAN HA, SUTHERLAND D, BACON R, MCGEHEE W. Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity to a generally applicable assay for activated protein C resistance. Br J Haematol 1996: 95: 550-553.